CCR5 Antibodies HGS004 and HGS101 Preferentially Inhibit Drug-Bound CCR5 Infection and Restore Drug Sensitivity of Maraviroc Resistant HIV-1 in Primary Cells

被引：0
|
作者：
Latinovic, Olga [1 ]
Le, Nhut [1 ]
Heredia, Alonso [1 ]
Redfield, Robert R. [1 ]
机构：
[1] Inst Human Virol, Baltimore, MD USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2012年 / 59卷
关键词：
D O I：
10.1097/01.qai.0000413784.36588.07
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A5
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells
    Latinovic, Olga
    Reitz, Marvin
    Le, Nhut M.
    Foulke, James S.
    Faetkenheuer, Gerd
    Lehmann, Clara
    Redfield, Robert R.
    Heredia, Alonso
    VIROLOGY, 2011, 411 (01) : 32 - 40
  • [2] Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Latinovic, Olga
    Le, Nhut
    Reitz, Marvin
    Pal, Ranajit
    DeVico, Anthony
    Foulke, James S.
    Redfield, Robert R.
    Heredia, Alonso
    AIDS, 2011, 25 (09) : 1232 - 1235
  • [3] HIV-1 isolates resistant to CCR5 antagonists demonstrate increased affinity for the drug-bound coreceptor
    Buontempo, P. J.
    Wojcik, L.
    Buontempo, C.
    Strizki, J.
    Ralston, R.
    ANTIVIRAL THERAPY, 2007, 12 : S135 - S135
  • [4] HIV-1 isolates resistant to CCR5 antagonists demonstrate increased affinity for the drug-bound coreceptor
    Buontempo, P. J.
    Wojcik, L.
    Buontempo, C.
    Strizki, J.
    Ralston, R.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S135 - S135
  • [5] A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
    Tilton, John C.
    Wilen, Craig B.
    Didigu, Chukwuka A.
    Sinha, Rohini
    Harrison, Jessamina E.
    Agrawal-Gamse, Caroline
    Henning, Elizabeth A.
    Bushman, Frederick D.
    Martin, Jeffrey N.
    Deeks, Steven G.
    Doms, Robert W.
    JOURNAL OF VIROLOGY, 2010, 84 (20) : 10863 - 10876
  • [6] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [7] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [8] Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor
    Jiang, Xiaowei
    Feyertag, Felix
    Meehan, Conor J.
    McCormack, Grace P.
    Travers, Simon A.
    Craig, Charles
    Westby, Mike
    Lewis, Marilyn
    Robertson, David L.
    JOURNAL OF VIROLOGY, 2015, 89 (22) : 11457 - 11472
  • [9] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [10] Drug evaluation: Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS
    Meanwell, Nicholas A.
    Kadow, John F.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (08) : 669 - 681
12345